Key regions: Europe, India, Canada, Italy, South Korea
Bronchodilator drugs are widely used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Portugal, the market for bronchodilator drugs has been growing steadily in recent years.
Customer preferences: Patients suffering from respiratory diseases in Portugal prefer bronchodilator drugs as they provide quick relief from symptoms such as shortness of breath, wheezing, and coughing. Moreover, these drugs are available in various forms such as inhalers, tablets, and syrups, making them convenient for patients to use.
Trends in the market: The bronchodilator drugs market in Portugal has been witnessing a shift towards combination therapies. Combination therapies involve the use of two or more drugs to treat respiratory diseases. This trend is driven by the need for more effective treatment options and the desire to simplify treatment regimens for patients. Moreover, the market is also witnessing the introduction of new bronchodilator drugs with improved efficacy and safety profiles.
Local special circumstances: The prevalence of respiratory diseases in Portugal is higher than the European average. According to the European Lung Foundation, Portugal has one of the highest asthma prevalence rates in Europe. This high prevalence of respiratory diseases has led to a significant demand for bronchodilator drugs in the country.
Underlying macroeconomic factors: The Portuguese healthcare system has been undergoing reforms in recent years, aimed at improving the efficiency and effectiveness of healthcare services. These reforms have led to an increase in the availability of healthcare services and the adoption of new technologies. Moreover, the government has been investing in the development of the pharmaceutical industry, which has led to the growth of the bronchodilator drugs market in the country.In conclusion, the bronchodilator drugs market in Portugal is driven by the high prevalence of respiratory diseases in the country and the availability of new and more effective treatment options. The market is expected to continue to grow in the coming years, driven by the increasing demand for combination therapies and the government's continued investment in the healthcare and pharmaceutical sectors.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
